New Developments in Myeloma Treatment and Response Assessment

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) important news in multiple myeloma treatment; (2) the prognostic value of FDG PET/CT in different disease stages; and (3) the added value of non-FDG tracer imaging, radiomics, and whole-body functional MRI. Financial Disclosure: This work has been supported in part by grants from the French National Agency for Research “France 2030 investment plan” Labex IRON (ANR-11-LABX-18-01), Equipex ArronaxPlus (ANR-11-EQPX-0004), and I-SITE NExT (ANR-16-IDEX-0007) and by a grant from INCa-DGOS-INSERM_12558 (SIRIC ILIAD). Dr. Moreau has received honoraria from or is on the advisory boards for Janssen, Celgene, Sanofi, Abbvie, Takeda, Amgen, and GSK. Dr. Nanni is a consultant for Sanofi-Aventis, a case revisor for Keosys, and on the advisory board for the EANM Oncology Theranostic Committee and the AIMN Oncology Committee. Dr. Kraeber-Bodere is a consultant for PentixaPharm and Novartis-AAA, a case revisor for Keosys, and a member of the EANM Oncology Theranostic Committee. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through September 2026.